New combo aims to stop AML from coming back
NCT ID NCT07537257
First seen Apr 23, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study tests whether adding venetoclax to standard chemotherapy can help keep acute myeloid leukemia (AML) from returning. It is for adults aged 18 to 65 who are already in remission after initial treatment. The goal is to see if the combination leads to fewer cancer cells left behind and better long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOGENOUS LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Hematology, Guangdong Second Provincial General Hospital
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.